Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication

Interferon alpha (IFN-α)-based therapy is the currently approved treatment for chronic hepatitis C viral infection. The sustained antiviral response rate is approximately 50% for genotype-1 infection. The major challenge to the HCV community is to improve antiviral efficacy and to reduce the side ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Haizhen, Butera, Mike, Nelson, David R, Liu, Chen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232870/
https://www.ncbi.nlm.nih.gov/pubmed/16146571
http://dx.doi.org/10.1186/1743-422X-2-80

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232870/
https://www.ncbi.nlm.nih.gov/pubmed/16146571
http://dx.doi.org/10.1186/1743-422X-2-80

Ejemplares similares